• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychiatric research >Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: Anaturalistic comparative study
【24h】

Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: Anaturalistic comparative study

机译：选择性5-羟色胺再摄取抑制剂在儿童和青少年抵抗性抽动相关的强迫症中的抗精神病药增强作用：自然比较研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study is to assess efficacy of augmentation of SSRIs with risperidone or aripiprazole in youths with tic-related Obsessive-Compulsive Disorder (OCD) non responders to an SSRI monotherapy. 120 consecutive patients (age range 7-18 years) were treated with an SSRI monotherapy for at least 12 weeks, 51 (42.5%) were responders, and the 69 non-responders (mean age 13.7±2.4 years) were included in this study. 35 patients received an augmentation with risperidone (1.7±.8mg/day), and 34 with aripiprazole (8.9±3.1mg/day) for 12 weeks. Regarding the OCD symptomatology, at the endpoint the Clinical Global Impression-Severity score (CGI-S) improved from 5.6±.8 (severely ill), to 3.2±.9 (mild to moderately ill) (p<.0001), and the Children-Global Assessment Scale (C-GAS) from 40.3±5.2 to 53.8±9.2 (p<.0001). Thirty-nine patients (56.5%) were responders in OCD symptomatology (CGI-I score 1 or 2, CGI-S score 3 or less and C-GAS score 50 or more during three consecutive months after a 12-week treatment). Compared to non responders, they were less impaired at the baseline in CGI-S (p<.0001) and C-GAS (p<.0001). Subtypes of OCD and comorbidity did not affect the response. No differences were found between risperidone and aripiprazole augmentation. 47 patients (68.1%) significantly improved tics, without differences between risperidone and aripiprazole. None discontinued medications because of side effects, but risperidone was associated with weight gain and sedation, and aripiprazole to mild/moderate agitation. In tic-related pediatric OCD, augmentation of SSRIs with risperidone or aripiprazole was tolerated and effective in about half of the patients non responding to an SSRI.
机译：这项研究的目的是评估对抽动相关强迫症（OCD）无反应的SSRI单一疗法的年轻人，使用利培酮或阿立哌唑增强SSRI的疗效。连续120例患者（年龄介于7-18岁之间）接受SSRI单一疗法治疗至少12周，其中有51例（42.5％）是有反应者，本研究包括69例无反应者（平均年龄13.7±2.4岁） 。 35例患者接受了利培酮（1.7±.8mg /天）增强治疗，34例接受阿立哌唑（8.9±3.1mg /天）增强治疗，持续12周。关于OCD症状，在终点，临床总体印象严重度评分（CGI-S）从5.6±.8（重症）提高到3.2±.9（轻度至中度）（p <.0001），并且儿童全球评估量表（C-GAS）从40.3±5.2降至53.8±9.2（p <.0001）。在12周治疗后的连续三个月中，有39例患者（56.5％）对OCD症状有反应（CGI-I得分为1或2，CGI-S得分为3或更低，C-GAS得分为50或更高）。与无反应者相比，在CGI-S（p <.0001）和C-GAS（p <.0001）的基线他们受到的损害较小。强迫症的亚型和合并症不影响反应。利培酮和阿立哌唑增效之间未发现差异。 47例患者（68.1％）的抽动显着改善，利培酮和阿立哌唑之间无差异。没有人会因为副作用而停药，但利培酮与体重增加和镇静有关，而阿立哌唑与轻度/中度激动有关。在抽动相关的小儿强迫症中，利培酮或阿立哌唑对SSRIs的增强是可以耐受的，并且对约半数对SSRI无反应的患者有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号